<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2356">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321616</url>
  </required_header>
  <id_info>
    <org_study_id>118684</org_study_id>
    <nct_id>NCT04321616</nct_id>
  </id_info>
  <brief_title>The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients</brief_title>
  <official_title>The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a
      multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy
      of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients
      diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional
      efficacy, safety and explorative endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An open randomized adaptive controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>3 weeks</time_frame>
    <description>All cause in-hospital mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and duration of mechanical ventilation</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and duration of intensive care unit (ICU) treatment</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital admittance</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 Day mortality</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of co-infections</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of organ dysfunction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory and anti-inflammatory mediators as assessed in serum and plasma</measure>
    <time_frame>Throughout hospitalization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Markers of extracellular matrix remodeling</measure>
    <time_frame>Throughout hospitalization and 3 months after remission</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Markers of endothelial activation</measure>
    <time_frame>Throughout hospitalization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Markers of platelet activation</measure>
    <time_frame>Throughout hospitalization</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>COVID 19</condition>
  <condition>Acute Respiratory Distress Syndrome ARDS</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remdesivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group - SoC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.</description>
    <arm_group_label>Control group - SoC</arm_group_label>
    <arm_group_label>Remdesivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.</description>
    <arm_group_label>Control group - SoC</arm_group_label>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>(Standard of Care) SoC</intervention_name>
    <description>The standard of care will be supplied to all patients not receiving a drug intervention.</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_label>Remdesivir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients, 18 years and above

          2. Confirmed SARS-2-CoV-2 infection by PCR

          3. Admitted to the hospital ward or the ICU

          4. Subjects (or legally authorized representative) provides written informed consent
             prior to initiation of the study

        Exclusion Criteria:

          1. Severe co-morbidity with life expectancy &lt;3 months according to investigators
             assessment

          2. (Aspartate Transaminase/ Alanine Aminotransferase) ASAT/ALAT &gt; 5 times the upper limit
             of normal

          3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction

          4. Known intolerance to the available study drugs

          5. Pregnancy, possible pregnancy or breast feeding

          6. Any reason why, in the opinion of the investigators, the patient should not
             participate

          7. Subject participates in a potentially confounding drug or device trial during the
             course of the study

          8. Prolonged QT interval (&gt;450 ms)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aukrust, MD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Barratt-Due, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trine Kåsine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katerina Nezvalova-Henriksen, Pharm D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo Hospital Pharmacies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Margarita Dyrhol Riise, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marius Trøseid, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inge Christoffer Olsen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorCRIN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Aukrust, MD, Professor</last_name>
    <phone>0047 46778374</phone>
    <email>paukrust@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Barratt-Due, MD, PhD</last_name>
    <phone>0047 98209974</phone>
    <email>andreas.barrattdue@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Andreas Barratt-Due</name>
      <address>
        <city>Oslo</city>
        <zip>0756</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANDREAS BARRATT-DUE, PhD</last_name>
      <phone>+47 98209974</phone>
      <email>andreas.barrattdue@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pål Aukrust, PhD</last_name>
      <phone>+47 46778374</phone>
      <email>paukrust@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Barratt-Due</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Effect of drugs</keyword>
  <keyword>Adverse effects of drugs</keyword>
  <keyword>SARS-CoV clearance</keyword>
  <keyword>Duration of artificial ventilation</keyword>
  <keyword>Duration of intensive care stay</keyword>
  <keyword>Duration of hospital stay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All patients included in this study will automatically be included in the WHO COVID 19 protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The study will end according the requirements to WHO</ipd_time_frame>
    <ipd_access_criteria>WHO COVID 19 investigators</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

